{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.476","statisticalComment":"Analysis was based on stratified cox regression by ISS stage (I-II vs. III) and age (\\< 65y vs. ≥ 65y).","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of the confidence interval has not been reached.","groupId":"OG000","lowerLimit":"40.4","upperLimit":"NA","value":"52.6"},{"groupId":"OG001","lowerLimit":"41.0","upperLimit":"56.4","value":"47.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"Overall survival was defined as time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive melphalan, prednisone and thalidomide induction plus thalidomide maintenance (MPT-T).\n\nINDUCTION THERAPY: Patients receive melphalan PO and prednisone PO daily on days 1-4, and thalidomide PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE THERAPY: Patients receive thalidomide PO daily and continue in the absence of disease progression.","id":"OG000","title":"Arm I (MPT-T)"},{"description":"Patients receive lower-dose melphalan, prednisone and lenalidomide (Revlimid®) induction plus lenalidomide maintenance (mPR-R).\n\nINDUCTION THERAPY: Patients receive melphalan PO and prednisone PO daily on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE THERAPY: Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression.","id":"OG001","title":"Arm II (mPR-R)"}],"paramType":"MEDIAN","populationDescription":"Intention-to-treatment (ITT) population","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 10 years from the date of randomization.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}